Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)

China flag China · Delayed Price · Currency is CNY
29.36
+0.38 (1.31%)
At close: Mar 6, 2026
Market Cap6.66B +8.8%
Revenue (ttm)1.14B -2.3%
Net Income228.68M -8.6%
EPS1.01 -8.6%
Shares Out226.80M
PE Ratio29.12
Forward PE24.67
Dividend0.20 (0.69%)
Ex-Dividend DateJul 17, 2025
Volume2,873,900
Average Volume7,167,204
Open28.80
Previous Close28.98
Day's Range28.80 - 29.85
52-Week Range25.03 - 33.79
Beta0.33
RSI52.35
Earnings DateApr 27, 2026

About SHE:002880

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 198... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1985
Employees 859
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002880
Full Company Profile

Financial Performance

In 2024, SHE:002880's revenue was 1.20 billion, an increase of 14.75% compared to the previous year's 1.05 billion. Earnings were 253.52 million, an increase of 15.95%.

Financial Statements